Human immunodeficiency and Hodgkin lymphoma

Transfusion and Apheresis Science

Volumn 42, Issue 2, 2010, Pages 131-139

  Sissolak, Gerhard ^a   Sissolak, Dagmar ^a   Jacobs, Peter ^a,b,c,d  

^a Faculty of Health Sciences   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d The Department of Haematology   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DIDEOXINOSYNE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHYLPREDNISOLONE; NAVELBINE; PREDNISONE; PROCARBAZINE; RITUXIMAB; THALIDOMIDE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LEUKEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFERTILITY; KAPOSI SARCOMA; LYMPH NODE BIOPSY; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PREGNANCY; STEM CELL TRANSPLANTATION; UNSPECIFIED SIDE EFFECT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; HIV; HODGKIN DISEASE; HUMANS;

EID: 77949656967     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2010.01.008     Document Type: Article

References (122)

1. Gottlieb M.S., Schroff R., Schanker H.M., Weisman J.D., Fan P.T., Wolf R.A., et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 305 (1981) 1425-1431
2. Harris C., Small C.B., Klein R.S., Friedland G.H., Moll B., Emeson E.E., et al. Immunodeficiency in female sexual partners of men with the acquired immunodeficiency syndrome. N Engl J Med 308 (1983) 1181-1184
3. Stebbing J., and Bower M. What can oncologists learn from HIV?. Lancet Oncol 4 (2003) 438-445
4. Ziegler J.L., Templeton A.C., and Vogel C.L. Kaposi's sarcoma: a comparison of classical, endemic, and epidemic forms. Semin Oncol 11 (1984) 47-52
5. Boring C.C., Brynes R.K., Chan W.C., Causey N., Gregory H.R., Nadel M.R., et al. Increase in high-grade lymphomas in young men. Lancet 1 (1985) 857-859
6. Levine A.M., Gill P.S., Meyer P.R., Burkes R.L., Ross R., Dworsky R.D., et al. Retrovirus and malignant lymphoma in homosexual men. JAMA 254 (1985) 1921-1925
7. Stebbing J., Marvin V., and Bower M. The evidence-based treatment of AIDS-related non-Hodgkin's lymphoma. Cancer Treat Rev 30 (2004) 249-253
8. Thirlwell C., Sarker D., Stebbing J., and Bower M. Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy. Clin Lymphoma 4 (2003) 86-92
9. Phelps R.M., Smith D.K., Heilig C.M., Gardner L.I., Carpenter C.C., Klein R.S., et al. Cancer incidence in women with or at risk for HIV. Int J Cancer 94 (2001) 753-757
10. Goedert J.J., Coté T.R., Virgo P., Scoppa S.M., Kingma D.W., Gail M.H., et al. Spectrum of AIDS-associated malignant disorders. Lancet 351 (1998) 1833-1839
11. Dal Maso L., and Franceschi S. Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol 4 (2003) 110-119
12. Powles T., Bower M., Daugaard G., Shamash J., de Ruiter A., Johnson M., et al. Multicenter study of human immunodeficiency virus-related germ cell tumors. J Clin Oncol 21 (2003) 1922-1927
13. International Agency for Research on Cancer (IARC). Human immunodeficiency viruses and human T-cell lymphotropic viruses. Lyon: IARC, 1996:261-390. (monographs on the evaluation of carcinogenic risks to humans; Vol. 67).
14. Engels E.A., Biggar R.J., Hall H.I., Cross H., Crutchfield A., Finch J.L., et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123 (2008) 187-194
15. Clifford G.M., Rickenbach M., Lise M., Dal Maso L., Battegay M., Bohlius J., et al. Hodgkin lymphoma in the Swiss cohort study. Blood 113 (2009) 5737-5742
16. Carbone A., Cesarman E., Spina M., Gloghini A., and Schulz T.F. HIV-associated lymphomas and gamma-herpesviruses. Blood 113 (2009) 1213-1224
17. UNAIDS. Report on the global AIDS epidemic. Geneva: UNAIDS; 2006.
18. National HIV and syphilis sero-prevalence survey of women attending public health antenatal clinics in South Africa. Pretoria: Department of Health; 2005. .
19. Thomas J.O. Acquired immunodeficiency syndrome-associated cancers in Sub-Saharan Africa. Semin Oncol 28 (2001) 198-206
20. Sissolak G., and Mayaud P. AIDS related Kaposi's sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa. Trop Med Int Health 10 (2005) 981-992
21. Sissolak G., Abayomi A., and Jacobs P. AIDS defining lymphomas in the era of highly active antiretroviral therapy (HAART)-an African perspective. Transfus Apher Sci 37 (2007) 63-70
22. Hessol N.A., Katz M.H., Liu J.Y., Buchbinder S.P., Rubino C.J., and Holmberg S.D. Increased incidence of Hodgkin disease in homosexual men with HIV infection. Ann Intern Med 117 (1992) 309-311
23. Klimm B., Schnell R., Diehl V., and Engert A. Current treatment and immunotherapy of Hodgkin's lymphoma. Haematologica 90 (2005) 1680-1692
24. Glaser S.L., Clarke C.A., Gulley M.L., Craig F.E., DiGiuseppe J.A., Dorfman R.F., et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998. Cancer 98 (2003) 300-309
25. Shisana O., Rehle T., Simbayi L., Parker W., Zuma K., Bhana A., et al. South African national HIV prevalence, HIV incidence, behaviour and communications survey (2005), Human Sciences Research Council, Cape Town
26. Clifford G.M., Polesel J., Rickenbach M., Dal Maso L., Keiser O., Kofler A., et al. Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97 (2005) 425-432
27. Engels E.A., Pfeiffer R.M., Goedert J.J., Virgo P., McNeel T.S., Scoppa S.M., et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 20 (2006) 1645-1654
28. Biggar R.J., Jaffe E.S., Goedert J.J., Chaturvedi A., Pfeiffer R., and Engels E.A. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108 (2006) 3786-3791
29. Grulich A.E., Li Y., McDonald A., Correll P.K., Law M.G., and Kaldor J.M. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 16 (2002) 1155-1161
30. Burgi A., Brodine S., Wegner S., Milazzo M., Wallace M.R., Spoone K., et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 104 (2005) 1505-1511
31. International Agency for Research on Cancer (IARC). Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8. Lyon: IARC; 1997 [Monographs on the evaluation of carcinogenic risks to humans; Vol. 70].
32. Dolcetti R., Boiocchi M., Gloghini A., and Carbone A. Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease. Eur J Cancer 37 (2001) 1276-1287
33. Boiocchi M., De Re V., Gloghini A., Vaccher E., Dolcetti R., Marzotto A., et al. High incidence of monoclonal EBV episomes in Hodgkin's disease and anaplastic large-cell KI-1-positive lymphomas in HIV-1-positive patients. Int J Cancer 54 (1993) 53-59
34. Spina M., Berretta M., and Tirelli U. Hodgkin's disease in HIV. Hematol Oncol Clin North Am 17 (2003) 843-858
35. Glaser S.L., Lin R.J., Stewart S.L., Ambinder R.F., Jarrett R.F., Brousset P., et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 70 (1997) 375-382
36. Engels E.A., Frisch M., Lubin J.H., Gail M.H., Biggar R.J., and Goedert J.J. Prevalence of hepatitis C virus infection and risk for hepatocellular carcinoma and non-Hodgkin lymphoma in AIDS. J Acquir Immune Defic Syndr 31 (2002) 536-541
37. Frisch M., Biggar R.J., and Goedert J.J. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92 (2000) 1500-1510
38. Vaccher E., Spina M., and Tirelli U. Clinical aspects and management of Hodgkin's disease and other tumours in HIV-infected individuals. Eur J Cancer 37 (2001) 1306-1315
39. Levine A.M. Hodgkin's disease in the setting of human immunodeficiency virus infection. J Natl Cancer Inst Monogr 23 (1998) 37-42
40. Andrieu J.M., Roithmann S., Tourani J.M., Levy R., Desablens B., le Maignan C., et al. Hodgkin's disease during HIV1 infection: the French registry experience. French registry of HIV-associated tumors. Ann Oncol 4 (1993) 635-641
41. Poluri A., Shah K.G., Carew J.F., Shaha A.R., Har-El G., Lucente F.E., et al. Hodgkin's disease of the head and neck in human immunodeficiency virus-infected patients. Am J Otolaryngol 23 (2002) 12-16
42. Diehl V. Hodgkin's disease-from pathology specimen to cure. N Engl J Med 357 (2007) 1968-1971
43. Hutchings M., Loft A., Hansen M., Pedersen L.M., Buhl T., Jurlander J., et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107 (2006) 52-59
44. Gallamini A., Rigacci L., Merli F., Nassi L., Bosi A., Capodanno T., et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 91 (2006) 475-481
45. Gallamini A., Hutchings M., Rigacci L., Specht L., Merli F., Hansen M., et al. Early Interim 2-[18F]Fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25 (2007) 3746-3752
46. Advani R., Maeda L., Lavori P., Quon A., Hoppe R., Breslin S., et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol 25 (2007) 3902-3907
47. Bonadonna G., Bonfante V., Viviani S., Di Russo A., Villani F., and Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 22 (2004) 2835-2841
48. Engert A., Franklin J., Eich H.T., Brillant C., Sehlen S., Cartoni C., et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 25 (2007) 3495-3502
49. Connors J.M. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 23 (2005) 6400-6408
50. Duggan D.B., Petroni G.R., Johnson J.L., Glick J.H., Fisher R.I., Connors J.M., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 21 (2003) 607-614
51. Canellos G.P., Anderson J.R., Propert K.J., Nissen N., Cooper M.R., Henderson E.S., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327 (1992) 1478-1484
52. Meyer R.M., Gospodarowicz M.K., Connors J.M., Pearcey R.G., Bezjak A., Wells W.A., et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: national cancer institute of Canada clinical trials group and the eastern cooperative oncology group. J Clin Oncol 23 (2005) 4634-4642
53. Evens A.M., Cilley J., Ortiz T., Gounder M., Houn N., Rademaker A., et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 137 (2007) 545-552
54. Martin W.G., Ristow K.M., Habermann T.M., Colgan J.P., Witzig T.E., and Ansell S.M. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 23 (2005) 7614-7620
55. Horning S.J., Hoppe R.T., Breslin S., Bartlett N.L., Brown B.W., and Rosenberg S.A. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 20 (2002) 630-637
56. Diehl V., Franklin J., Pfreundschuh M., Lathan B., Paulus U., Hasenclever D., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348 (2003) 2386-2395
57. Hasenclever D., Diehl V., Armitage J.O., Assouline D., Björkholm M., Brusamolino E., et al. A prognostic score for advanced Hodgkin's disease. N Engl J Med 339 (1998) 1506-1514
58. Wedgwood AR, Fanale MA, Fayad LE, McLaughlin P, Hagemeister FB, Pro B, et al. Rituximab + ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all international prognostic score (IPS) groups and in patients who have PET positive disease after 2-3 cycles of therapy. Blood 2007;110:71a [abstract 215].
59. Jones RJ, Lin L, Gocke C, Hensley K, Siedner M, Barber JP, et al. Clonotypic B cells circulate in Hodgkin's lymphoma (HL). Blood 2006;108:143a [Abstract 470].
60. Longo D.L., Duffey P.L., Young R.C., Hubbard S.M., Ihde D.C., Glatstein E., et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10 (1992) 210-218
61. Bonfante V., Santoro A., Viviani S., Devizzi L., Balzarotti M., Soncini F., et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 15 (1997) 528-534
62. Roach M., Brophy N., Cox R., Varghese A., and Hoppe R.T. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J Clin Oncol 8 (1990) 623-629
63. Mauch P., Tarbell N., Skarin A., Rosenthal D., and Weinstein H. Wide-field radiation therapy alone or with chemotherapy for Hodgkin's disease in relapse from combination chemotherapy. J Clin Oncol 5 (1987) 544-549
64. Roach M., Kapp D.S., Rosenberg S.A., and Hoppe R.T. Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease. J Clin Oncol 5 (1987) 550-555
65. Lohri A., Barnett M., Fairey R.N., O'Reilly S.E., Phillips G.L., Reece D., et al. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood 77 (1991) 2292-2298
66. Yuen A.R., Rosenberg S.A., Hoppe R.T., Halpern J.D., and Horning S.J. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 89 (1997) 814-822
67. Kuruvilla J., Song K., Mollee P., Panzarella T., McCrae J., Nagy T., et al. A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology 11 (2006) 25-29
68. Schulz H., Rehwald U., Morschhauser F., Elter T., Driessen C., Rüdiger T., et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 111 (2008) 109-111
69. Linch D.C., Winfield D., Goldstone A.H., Moir D., Hancock B., McMillan A., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 341 (1993) 1051-1054
70. Sureda A., Constans M., Iriondo A., Arranz R., Caballero M.D., Vidal M.J., et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 16 (2005) 625-633
71. Moskowitz C.H., Kewalramani T., Nimer S.D., Gonzalez M., Zelenetz A.D., and Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 124 (2004) 645-652
72. Bartlett N.L., Niedzwiecki D., Johnson J.L., Friedberg J.W., Johnson K.B., van Besien K., et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 18 (2007) 1071-1079
73. Kuruvilla J., Nagy T., Pintilie M., Tsang R., Keating A., and Crump M. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 106 (2006) 353-360
74. Somers R., Carde P., Henry-Amar M., Tarayre M., Thomas J., Hagenbeek A., et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European organization for research and treatment of cancer lymphoma cooperative group and groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 12 (1994) 279-287
75. Loeffler M., Brosteanu O., Hasenclever D., Sextro M., Assouline D., Bartolucci A.A., et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International database on Hodgkin's disease overview study group. J Clin Oncol 16 (1998) 818-829
76. Fermé C., Sebban C., Hennequin C., Diviné M., Lederlin P., Gabarre J., et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 trial. Blood 95 (2000) 2246-2252
77. Horning S.J., Williams J., Bartlett N.L., Bennett J.M., Hoppe R.T., Neuberg D., et al. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: eastern cooperative oncology group pilot study E1492. J Clin Oncol 18 (2000) 972-980
78. Hancock S.L., and Hoppe R.T. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 6 (1996) 225-242
79. Metayer C., Lynch C.F., Clarke E.A., Glimelius B., Storm H., Pukkala E., et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 18 (2000) 2435-2443
80. van Leeuwen F.E., Klokman W.J., Veer M.B., Hagenbeek A., Krol A.D., Vetter U.A., et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 18 (2000) 487-497
81. Dores G.M., Metayer C., Curtis R.E., Lynch C.F., Clarke E.A., Glimelius B., et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 20 (2002) 3484-3494
82. Aleman B.M., van den Belt-Dusebout A.W., Klokman W.J., van't Veer M.B., Bartelink H., and van Leeuwen F.E. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21 (2003) 3431-3439
83. van Leeuwen FE, Swerdlow AJ, Valagussa P, Tucker MA. Second cancers after treatment of Hodgkin's disease. In: Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM, editors. Hodgkin's disease. Philadelphia: Lippincott Williams and Wilkins; 1999: 607-32.
84. Kaldor J.M., Day N.E., Clarke E.A., van Leeuwen F.E., Henry-Amar M., Fiorentino M.V., et al. Leukemia following Hodgkin's disease. N Engl J Med 322 (1990) 7-13
85. Bruce L.J., and Hancock B.W. Immunity in Hodgkin's disease: status after 10 years' remission. Br J Cancer 62 (1990) 324-325
86. Hoppe R.T., Fuks Z.Y., Strober S., and Kaplan H.S. The long term effects of radiation of T and B lymphocytes in the peripheral blood after regional irradiation. Cancer 40 (1977) 2071-2078
87. van Leeuwen F.E., Klokman W.J., Stovall M., Hagenbeek A., van den Belt-Dusebout A.W., Noyon R., et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 87 (1995) 1530-1537
88. Kawabata I., Takahashi Y., Iwagaki S., and Tamaya T. MRI during pregnancy. J Perinat Med 31 (2003) 449-458
89. Levine D. Obstetric MRI. J Magn Reson Imaging 24 (2006) 1-15
90. Hicks R.J., Binns D., and Stabin M.G. Pattern of uptake and excretion of 18F-FDG in the lactating breast. J Nucl Med 42 (2001) 1238-1242
91. Benveniste H., Fowler J.S., Rooney W.D., Moller D.H., Backus W.W., Warner D.A., et al. Maternal-fetal in vivo imaging: a combined PET and MRI study. J Nucl Med 44 (2003) 1522-1530
92. Weisz B., Meirow D., Schiff E., and Lishner M. Impact and treatment of cancer during pregnancy. Exper Rev Anticancer Ther 4 (2004) 889-902
93. Cardonick E., and Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 5 (2004) 283-291
94. Doll D.C., Ringenberg Q.S., and Yarbro J.W. Management of cancer during pregnancy. Arch Intern Med 148 (1998) 2058-2064
95. Randall T. National registry seeks scarce data on pregnancy outcomes during chemotherapy. JAMA 269 (1993) 323
96. Aviles A., and Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma 2 (2001) 173-177
97. Weisz B., Schiff E., and Lishner M. Cancer in pregnancy: maternal and fetal implications. Hum Reprod Update 7 (2001) 384-393
98. Lishner M., Zemlickis D., Degendorfer P., Panzarella T., Sutcliffe S.B., and Koren G. Maternal and foetal outcome following Hodgkin's disease in pregnancy. Br J Cancer 65 (1992) 114-117
99. Zemlickis D., Lishner M., Degendorfer P., Panzarella T., Sutcliffe S.B., and Koren G. Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med 152 (1992) 573-576
100. Fenig E., Mishaeli M., Kalish Y., and Lishner M. Pregnancy and radiation. Cancer Treat Rev 27 (2001) 1-7
101. Kal H.B., and Struikmans H. Radiotherapy during pregnancy: fact and fiction. Lancet Oncol 6 (2005) 328-333
102. Sifakis S., Angelakis E., Vardaki E., Koumantaki Y., Matalliotakis I., and Koumantakis E. Erythropoietin in the treatment of iron deficiency anemia during pregnancy. Gynecol Obstet Invest 51 (2001) 150-156
103. Cheung M.C., Pantanowitz L., and Dezube B.J. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist 10 (2005) 412-426
104. Levine A.M., Li P., Cheung T., Tulpule A., Von Roenn J., Nathwani R.N., et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr 24 (2000) 444-450
105. Tanaka P.Y., Pessoa Jr. V.P., Pracchia L.F., Buccheri V., Chamone D.A., and Calore E.E. Hodgkin lymphoma among patients infected with HIV in post-HAART era. Clin Lymphoma Myeloma 7 (2007) 364-368
106. Hoffmann C., Chow K.U., Wolf E., Faetkenheuer G., Stellbrink H.J., van Lunzen E., et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol 125 (2004) 455-462
107. Gerard L., Galicier L., Boulanger E., Quint L., Lebrette M.G., Mortier E., et al. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. AIDS 17 (2003) 81-87
108. Xicoy B., Ribera R.M., Miralles P., Berenguer J., Rubio R., Mahillo B., et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. GESIDA group and GELCAB group. Haematologica 92 (2007) 191-198
109. Gastaldi R., Martino P., Gentile G., Picardi V., De Propios M.S., Pirillo M.F., et al. Hodgkin's disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony-stimulating factor. Ann Oncol 13 (2002) 1158-1160
110. Gaidano G., Carbone A., and Dalla-Favera R. Pathogenesis of AIDS-related lymphomas. Am J Pathol 152 (1998) 623-630
111. Hartmann P., Rehwald U., Salzberger B., Franzen C., Sieber M., Wöhrmann A., et al. BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol 14 (2003) 1562-1569
112. Spina M., Gabarre J., Rossi G., Fasan M., Chiantarelli C., Nigra E., et al. Stanford V and concomitant HAART in 59 patients with Hodgkin's disease and HIV infection. Blood 100 (2002) 1984-1988
113. Spina M., Rossi G., Antinori A., Allione B., Fasan M., Rizzardini G., et al. VEBEP regimen and highly active antiretroviral therapy (HAART) in patients with HD and HIV Infection (HD-HIV). Blood 106 (2005) 100a
114. Spina M., Re A., Vaccher E., Gabarre J., and Tirelli U. High international prognostic score predicts a worse outcome for patients with Hodgkin's disease and HIV infection: results of a prospective study with Stanford V regimen. Ann Oncol 14 (2003) 655-656
115. Hasenclever D., and Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 339 (1998) 1506-1514
116. Errante D., Gabarre J., Ridolfo A.L., Rossi G., Nosari A.M., Gisselbrecht C., et al. Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSG. Ann Oncol 10 (1999) 189-195
117. Errante D., Tirelli U., Gastaldi R., Milo D., Nosari A.M., Rossi G., et al. Combined antineoplastic and anti-retroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection. A prospective study of 17 patients. The Italian cooperative group on AIDS and tumors (GICAT). Cancer 73 (1994) 437-444
118. Sissolak G, Andrews S, Abayomi A, Jacobs P. Haematopoietic and cardiovascular complications in patients infected with the human immunodeficiency virus Resources Cardiovasc Sci 2009; 17p.
119. Hammer S.M., Saag M.S., Schechter M., Montaner J.S., Schooley R.T., Jacobsen D.M., et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS society-USA panel. JAMA 296 (2006) 827-843
120. Mellors J.W., Munoz A., Giorgi J.V., Margolick J.W., Tassoni C.J., Gupta P., et al. Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126 (1997) 946-954
121. Gallant J.E. Should antiretroviral therapy be started earlier?. Curr HIV/AIDS Rep 4 (2007) 53-59
122. Mbulaiteye S.M., Biggar R.J., Goedert J.J., and Engels E.A. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 32 (2003) 527-533